While the government has threatened to implement regulations to control drug prices, the private sector is in a position to “leverage greater use of structured methodologies” to deploy their own solutions, Precision Value & Health’s Larry Blandford writes in an article published on the Journal of Clinical Pathways.
One key obstacle facing value assessments, he writes, is the failure of assessment models to evolve.
“In an environment where all payers are pushing toward a value-based system, we must elevate our diligence in assessing value, both by incorporating structured methodologies as well as updating when new evidence becomes available,” Blandford writes.
To read the full article on the Journal of Clinical Pathways, click here.
